Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.

Date publication

janvier 2017

Journal

British journal of cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FAVIER Laure , Dr KAMINSKY Marie-Christine

Tous les auteurs :
Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, Priou F, Tazi Y, Floquet A, Selle F, Berton-Rigaud D, Lesoin A, Kalbacher E, Lortholary A, Favier L, Treilleux I, Ray-Coquard I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28072765

Résumé

Backround:Patients with metastatic endometrial carcinoma have a poor prognosis and PIK3CA mutations and amplifications are common in these cancers. This study evaluated the efficacy and safety of the pure PI3K inhibitor BKM120 in advanced or recurrent endometrial carcinoma.

Référence

Br. J. Cancer. 2017 Jan;116(3):303-309